摘要
目的观察二甲双胍和吡格列酮对新诊断2型糖尿病(T2DM)患者血清chemerin的影响。方法将82例新诊断未应用抗糖尿病药物治疗的T2DM患者随机均分为两组,在统一的饮食、运动指导下,吡格列酮组给予吡格列酮30mg/d,二甲双胍组给予二甲双胍1000mg/d。分别于治疗前和治疗后3个月检测血清chemerin浓度、血糖、血脂等指标。结果两组治疗前后腰围、体重、BMI、血压、TC、TG、HDL-C等指标无统计学差异(P>0.05)。与治疗前比较,两组治疗后HbA1c、FBG、FIns、chemerin、HOMA-IR均降低,胰岛β细胞功能指数(HOMA-β)改善(P<0.05或P<0.01)。治疗后,两组HOMA-IR、HOMA-β比较均有统计学差异(P<0.05),而chemerin比较差异无统计学意义(P>0.05)。结论吡格列酮和二甲双胍虽然降低新诊断T2DM患者血清chemerin水平的机制不同,但作用相当。
Objective To observe the effect of metformin and pioglitazone on serum chemerin in the patients with newly diagnosed type 2 diabetes mellitus(T2 DM).Methods Eighty-two patients with newly diagnosed T2 DM without using antidiabetic drugs were randomly divided into two groups.On the basis of dietotherapy and kinetotherapy,group A was given pioglitazone 30 mg/d and group B was given metformin 1000 mg/d.Serum chemerin concentration,blood glucose,blood lipids and other relevant indicators were measured before treatment and 3 months after treatment.Results There were no significant differences in waist circumference,body weight,BMI,BP,TC,TG,and HDL-C before and after treatment between two groups(P>0.05).Compared with before,HbA1 c,FBG,FIns,chemerin and HOMA-IR were decreased after treatment,and HOMA-βwas improved in two groups(P<0.05 or P<0.01).After treatment,HOMA-IR and HOMA-βhad significant differences between two groups(P<0.05),but there was no significant difference in serum level of chemerin(P>0.05).Conclusion Although pioglitazone and metformin have different mechanisms for reducing serum chemerin levels in the patients with newly diagnosed T2 DM,the two drugs have a comparable efficacy on serum chemerin level.
作者
王峥
张金华
徐方江
WANG Zheng;ZHANG Jinhua;XU Fangjiang(Department of Endocrinology,Central Hospital of Linyi,Yishui 276400,CHINA)
出处
《江苏医药》
CAS
2019年第10期1048-1050,共3页
Jiangsu Medical Journal
